Compounded Semaglutide vs Brand Wegovy: Price, Safety, and What to Know in 2026

Updated May 2, 2026

The number one question people ask when they start researching GLP-1 weight-loss medications: why is compounded semaglutide $99–$275 a month while brand Wegovy lists at $1,350 — and is the cheap one safe?

The honest answer is more nuanced than either side wants you to believe. Compounded semaglutide is legitimately the same active molecule as Wegovy, regulated by the FDA, and used safely by hundreds of thousands of patients. It's also not the same finished drug product, not subject to the same manufacturing oversight, and could become unavailable if the FDA changes its shortage determination. This guide walks through the price gap, the regulatory landscape, the real safety considerations, and how to decide which makes sense for your situation.

The Price Gap: Concrete Numbers

The headline difference is roughly 70–85%. Specifics depend on dose, source, and whether you have insurance.

The savings difference between brand and compounded ranges from about $1,050/month at the extremes (Wegovy retail vs Hims oral) to roughly $0/month if you have commercial insurance that covers Wegovy and you qualify for the savings card.

What Is Compounded Semaglutide?

"Compounded" is a regulatory term, not a quality term. It refers to medications mixed by licensed pharmacists in response to a specific prescription, rather than mass-manufactured by a drug company. There are two relevant categories:

• 503A pharmacies compound prescriptions for individual patients on a per-order basis. They're licensed by state pharmacy boards and inspected by the FDA, but they don't make medications under the same continuous-process oversight as drug manufacturers.
• 503B outsourcing facilities compound in larger batches for distribution to clinics or telehealth platforms. They're held to current Good Manufacturing Practice (cGMP) standards, which are closer (but not identical) to brand-name pharmaceutical manufacturing.

Compounded semaglutide is currently legal because semaglutide has been on the FDA's drug shortage list. Federal law allows compounders to produce a drug that's in shortage, even if the brand-name version is FDA-approved. When the shortage ends, that allowance lapses.

Brand Wegovy: What You're Paying For

Wegovy is Novo Nordisk's branded weight-management semaglutide, FDA-approved in 2021. The list price reflects:

• cGMP manufacturing: Every batch is produced under continuous oversight with batch records, stability testing, and FDA-mandated quality controls.
• Clinical trial data: Wegovy went through Phase 1, 2, and 3 trials before approval. The labeling reflects what the trials showed, not extrapolation.
• FDA-approved label: Indication, dosing, contraindications, and side-effect profile are reviewed and updated by the FDA, not the manufacturer alone.
• AutoInjector pen: The pre-filled pen is engineered for accurate dosing and is included in the per-fill price.
• Manufacturer accountability: If something goes wrong with a batch, Novo Nordisk has a recall and patient-notification infrastructure.

For people with insurance that covers Wegovy, the savings card brings copay to $25/mo and the price-vs-quality calculation tilts strongly toward brand. For uninsured shoppers, the calculation is harder.

Safety: How to Think About It

Compounded semaglutide is not unsafe by default. The FDA does inspect compounding pharmacies. The active molecule is the same as Wegovy and Ozempic. But the safety guarantees are weaker than for brand-name medications, and there have been documented cases of compounded GLP-1s with potency issues, dosing errors, or contamination at lower-quality compounders.

Red flags to watch for

• Telehealth providers that won't tell you which compounding pharmacy supplies them
• "Semaglutide blends" with B12, glycine, or other additives marketed as enhancements (these often have less safety data than plain semaglutide)
• Prices significantly lower than the $79–$99/mo floor — quality compounding has real costs
• No requirement to check labs before starting or refilling
• No mechanism to reach a prescriber if you have side effects

What to verify before you start

• The compounding pharmacy is licensed in the state where you live
• The pharmacy is registered with the FDA (503A or 503B)
• The pharmacy provides a Certificate of Analysis showing the batch's potency and purity testing
• The telehealth provider has a process for prescriber follow-up if issues arise

Reputable providers like Strut Health, Yucca Health, Sprout Health, Hims, and Ro all name their compounding partners and have prescriber-messaging built in.

Cost Breakdown by Scenario

Scenario 1: You have commercial insurance that covers Wegovy

Brand Wegovy wins. The savings card drops your copay to $25/mo, which beats every compounded option. Confirm coverage by calling your insurance or asking your prescriber to run a benefits check before assuming the savings card will apply.

Scenario 2: You have commercial insurance that doesn't cover Wegovy

Compounded usually wins. The savings card on a non-covered plan offers limited Novo Nordisk savings, but compounded providers like Strut, Hims, Yucca, and Sprout will still beat the net price. Worth applying for prior authorization first — it sometimes succeeds.

Scenario 3: You're uninsured

Compounded is the practical answer. Even at the higher tiers ($199–$299/mo), it's well below the $349–$1,350 brand-name range. If you're income-qualified, the NovoCare Patient Assistance Program can provide brand Wegovy free, but the application takes 4–8 weeks to process, so compounded is often the bridge.

Scenario 4: You're on Medicare

Currently neither path is great because Medicare doesn't cover Wegovy for weight management and savings cards don't work with government insurance. The Medicare GLP-1 Bridge program launches July 2026 and will cover Wegovy at $50/mo. Until then, compounded telehealth is often the cheapest path.

Scenario 5: Self-pay on a tight budget

Compounded is the answer. See our guide to GLP-1 medications under $200/month for every option in that price band, including the cheapest brand alternatives.

Where to Get Compounded Semaglutide

The major telehealth providers offering compounded semaglutide as of May 2026:

• Hims: Oral compounded from $79/mo; injectable tiers higher.
• Strut Health: Oral compounded from $99/mo with auto-refill.
• Ro Body Program: Compounded injectable from $149/mo first month, ~$299/mo ongoing.
• Yucca Health: Compounded "semaglutide+" formulation from $175/mo first month, $146–$275/mo ongoing.
• Sprout Health: Compounded semaglutide from $199/mo, no hidden fees.

Live prices for all of these update on our comparison tool — we don't bake them into article copy because they shift more often than we can rewrite.

Questions to ask before signing up

• Which compounding pharmacy supplies my medication, and is it 503A or 503B?
• What's included in the monthly fee — just medication, or also provider visits and lab work?
• Are there cancellation fees or commitment terms beyond month-to-month?
• What happens if I have side effects — can I reach a prescriber the same day?
• Does the price hold at higher doses, or does it tier up as my dose increases?

The Regulatory Landscape in 2026

The FDA listed semaglutide on its drug shortage page in 2022 due to demand outpacing Novo Nordisk's manufacturing capacity. As long as it remains on the shortage list, compounding pharmacies can legally produce semaglutide for individual patient prescriptions.

Tirzepatide was previously on the shortage list, but the FDA declared the shortage resolved in October 2024 and gave 503A/503B compounders deadlines to wind down. That's why compounded tirzepatide is much harder to find than compounded semaglutide in 2026.

If the FDA declares the semaglutide shortage resolved — which Novo Nordisk has been pushing for — the compounded market would need to wind down on a timeline similar to tirzepatide's. Most legal analysts expect the shortage status to remain unresolved through at least the end of 2026, but it's not guaranteed.

Translation: compounded semaglutide is a real and legal option in 2026, but it's not necessarily a permanent one. If you start on it, have a fallback plan in mind for what you'd do if it became unavailable.

How to Decide

1. Check insurance first. Call your plan or have your prescriber run a benefits check on Wegovy. If covered, the savings card path beats every compounded option.
2. If not covered, check PAP eligibility. The NovoCare PAP is income-based and provides free Wegovy. Application takes 4–8 weeks.
3. If neither works, use compounded. Pick a provider that names its compounding pharmacy, has prescriber access for side effects, and prices transparently. Hims, Ro, Strut, Yucca, and Sprout all qualify.
4. Plan for the regulatory exit. If the shortage ends, you may need to switch to brand. Use our Wegovy without insurance guide to keep the brand fallback in mind.

Frequently Asked Questions

Is compounded semaglutide the same as Wegovy?

Compounded semaglutide contains the same active ingredient as Wegovy, but it is not the same FDA-approved drug product. Brand Wegovy is manufactured by Novo Nordisk under cGMP standards and goes through FDA review for safety, purity, and potency. Compounded semaglutide is mixed by licensed compounding pharmacies under a doctor's prescription; it is regulated, but not approved as a finished product the way Wegovy is.

Will compounded semaglutide be banned?

Probably not banned, but legally restricted. Compounded semaglutide is currently legal because the FDA placed semaglutide on its drug shortage list, which permits 503A and 503B compounders to produce it. If the shortage is resolved, the FDA can require compounders to wind down production. As of mid-2026, the shortage status is unresolved and most major telehealth compounded channels remain operating.

How do I know if a compounding pharmacy is legitimate?

Verify three things: (1) the pharmacy is licensed in your state and lists its license number publicly; (2) it is registered with the FDA as a 503A or 503B facility (503B is held to higher manufacturing standards); (3) it provides a Certificate of Analysis on request showing the drug's potency and purity test results. Reputable telehealth providers will name their compounding partner; ask for it before subscribing.

Can I switch from compounded semaglutide to brand Wegovy?

Yes, and the dose generally translates directly because the active ingredient is the same. Switching makes the most sense if your insurance starts covering Wegovy or if your income qualifies you for Novo Nordisk's patient assistance program. Expect a new prescription and potentially a new prior authorization on the brand side. There's no clinical reason to taper off compounded before starting brand. See our guide to switching GLP-1 medications for the cost implications.